Arab Journal of Gastroenterology
Volume 11, Issue 3 , Pages 124-129 , September 2010

Portal vein thrombosis and haematemesis in chronic liver disease. Are P-selectin and PSGL-1 clues?

  • Hoda A. Sadek, MD

      Affiliations

    • Clinical and Chemical Pathology Department, Cairo University, Cairo, Egypt
    • ,
  • Bothaina S. Madkour, MD

      Affiliations

    • Clinical and Chemical Pathology Department, Cairo University, Cairo, Egypt
    • Haematology Department, Theodor Bilharz Research Institute, Giza, Egypt
    • ,
  • Iman A. Shaheen, MD

      Affiliations

    • Clinical and Chemical Pathology Department, Cairo University, Cairo, Egypt
    • ,
  • Abeya F. Saleh, MD

      Affiliations

    • Clinical and Chemical Pathology Department, Cairo University, Cairo, Egypt
    • Haematology Department, Theodor Bilharz Research Institute, Giza, Egypt
    • Corresponding Author InformationCorresponding author at: Haematology Department, Theodor Bilharz Research Institute, Giza, Egypt.
    • ,
  • Rabab F. Yaseen

      Affiliations

    • Clinical and Chemical Pathology Department, Cairo University, Cairo, Egypt
    • Haematology Department, Theodor Bilharz Research Institute, Giza, Egypt
    • ,
  • Emad El-Din A. Bayoumi, MD

      Affiliations

    • Clinical and Chemical Pathology Department, Cairo University, Cairo, Egypt
    • Hepatology Department, Theodor Bilharz Research Institute, Giza, Egypt
    • ,
  • Salwa M. Toima, MD

      Affiliations

    • Clinical and Chemical Pathology Department, Cairo University, Cairo, Egypt
    • Haematology Department, Theodor Bilharz Research Institute, Giza, Egypt

Received 8 March 2010 ,Accepted 6 July 2010.

References 

  1. Castelino DJ, Salem HH. Natural anticoagulants and the liver. J Gastroenterol Hepatol. 1997;12(1):77–83
  2. Carmassi F, De Negri F, Morale M, et al. Antithrombotic and antifibrinolytic effects of antithrombin III replacement in liver cirrhosis. Lancet. 1997;349(9058):1069
  3. Northup PG. Hypercoagulation in liver disease. Clin Liver Dis. 2009;13(1):109–116
  4. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-I in coagulation and thrombosis. Thromb Haemost. 2004;92(3):459–466
  5. Kneuer C, Ehrhardt C, Radomski MW, et al. Selectins–potential pharmacological targets?. Drug Discov Today. 2006;11(21–22):1034–1040
  6. Tacke F, Schoffski P, Trautwein C, et al. Plasma P-selectin levels are elevated in patients with chronic liver disease. Blood Coagul Fibrinolysis. 2003;14(4):319–325
  7. Itoh S, Susuki C, Takeshita K, et al. Redistribution of P-selectin glycoprotein ligand-1 (PSGL-1) in chemokine-treated neutrophils: a role of lipid microdomains. J Leukoc Biol. 2007;81(6):1414–1421
  8. Xu J, Cai J, Peek SF, et al. Characterization of equine P-selectin glycoprotein ligand-1 by using a specific monoclonal antibody. Vet Immunol Immunopathol. 2008;121(1–2):144–149
  9. Day YJ. Will platelets be the novel target of perioperative inflammation?. Acta Anaesthesiol Taiwanica. 2009;47(2):53–55
  10. Huang GS, Lin TC, Wang JY, et al. Lidocaine priming reduces ADP-induced P-selectin expression and platelet–leukocyte aggregation. Acta Anaesthesiol Taiwanica. 2009;47(2):56–61
  11. Kajimoto H, Nakazawa M, Murasaki K, et al. Increased P-selectin expression on platelets and decreased plasma thrombomodulin in Fontan patients. Circ J. 2009;73(9):1705–1710
  12. Snapp KR, Ding H, Atkins K, et al. A novel P-selectin glycoprotein ligand-1 monoclonal antibody recognizes an epitope within the tyrosine sulfate motif of human PSGL-1 and blocks recognition of both P- and L-selectin. Blood. 1998;91(1):154–164
  13. Gratama JW, van der Linden R, van der Holt B, et al. Analysis of factors contributing to the formation of mononuclear cell aggregates (“Escapees”) in flow cytometric immunophenotyping. Cytometry. 1997;29(3):250–260
  14. Moore KL. Structure and function of P-selectin glycoprotein ligand-1. Leuk Lymphoma. 1998;29(1–2):1–15
  15. Loreth RM, Seus C, Berger HH, et al. Plasma thrombomodulin concentrations in healthy persons depends on age and sex. Ann Hematol. 1997;74(Suppl. II):A89
  16. Tripodi A. Hemostasis abnormalities in liver cirrhosis: Myth or reality?. Pol Arch Med Wewn. 2008;118(7–8):445–448
  17. Ponziani FR, Zocco MA, Campanale C, et al. Portal vein thrombosis: insight into physiopathology, diagnosis and treatment. World J Gastroenterol. 2010;16(2):143–155
  18. Iba T, Nakarai E, Takayama T, et al. Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model. Crit Care. 2009;13(6):R203
  19. Amitrano L, Guardascione MA, Brancaccio V, et al. Coagulation disorders in liver disease. Semin Liver Dis. 2002;22(1):83–96
  20. Senzolo M, Burra P, Cholongitas E, et al. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol. 2006;12(48):7725–7736
  21. Panasiuk A, Zak J, Kasprzycka E, et al. Blood platelet and monocyte activations and relation to stages of liver cirrhosis. World J Gastroenterol. 2005;11(18):2754–2758
  22. Tang Z, Zhuo JG, Huang WF, et al. Detection of platelet Ca2+(i), CD62P, CD63 and plasma CD62P in cirrhosis patients. Zhonghua Gan Zang Bing Za Zhi. 2003;11(7):412–414
  23. Ogasawara F, Fusegawa H, Haruki Y, et al. Platelet activation in patients with alcoholic liver disease. Tokai J Exp Clin Med. 2005;30(1):41–48
  24. Vardareli E, Saricam T, Demirustu C, et al. Soluble P selectin levels in chronic liver disease: Relationship to disease severity. Hepatogastroenterology. 2007;54(74):466–469
  25. Panasiuk A, Prokopowicz D, Zak J, et al. Activation of blood platelets in chronic hepatitis and liver cirrhosis P-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4. Hepatogastroenterology. 2001;48(39):818–822
  26. Sozinov AS. Systemic endotoxemia during chronic viral hepatitis. Bull Exp Biol Med. 2002;133(2):153–155
  27. Wang L, Liu GJ, Chen YX, et al. Combined use of D-dimer and P-selectin for the diagnosis of splenic or portal vein thrombosis following splenectomy. Thromb Res. 2010;125(5):e206–e209
  28. Patel KN, Soubra SH, Bellera RV, et al. Differential role of von Willebrand factor and P-selectin on microvascular thrombosis in endotoxemia. Arterioscler Thromb Vasc Biol. 2008;28(12):2225–2230
  29. Zarbock A, Polanowska Grabowska RK, Ley K. Platelet–neutrophil-interactions: linking hemostasis and inflammation. Blood Rev. 2007;21(2):99–111
  30. Ferroni P, Mammarella A, Martini F, et al. Increased soluble P-selectin levels in hepatitis C virus-related chronic hepatitis: correlation with viral load. J Investig Med. 2001;49(5):407–412
  31. Davenpeck KL, Brummet ME, Hudson SA, et al. Activation of human leukocytes reduces surface P-selectin glycoprotein ligand-1 (PSGL-1,CD162) and adhesion to P-selectin in vitro. J Immunol. 2000;165(5):2764–2772
  32. Maugeri N, de Gaetano G, Barbanti M, et al. Prevention of platelet–polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. Haematologica. 2005;90(6):833–839
  33. Mitricǎ D, Drug VL, Prelipcean CC, et al. Hemostatic disorders in liver disease [Anomaliile hemostazei in suferinţele hepatice]. Rev Med Chir Soc Med Nat Iasi. 2008;112(2):313–320
  34. Sioulis A, Malindretos P, Makedou A, et al. Coagulation factors as biological risk markers of endothelial dysfunction. Association with the thrombotic episodes of chronic hemodialysis patients. Hippokratia. 2009;13(4):237–241
  35. He HY, Wang C, Pang BS. Effects of activated protein C on coagulation and fibrinolysis in rabbits with endotoxin induced acute lung injury. Chin Med J. 2008;121(24):2561–2565
  36. Esmon NL, Carroll RC, Esmon CT. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem. 1983;258(20):12238–12242

PII: S1687-1979(10)00087-0

doi: 10.1016/j.ajg.2010.07.005

Arab Journal of Gastroenterology
Volume 11, Issue 3 , Pages 124-129 , September 2010

Article Tools